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Abstract 
Purpose: To evaluate the antipsychotic drugs most commonly prescribed for schizophrenia patients in 
Peshawar, Pakistan and to analyze the treatment costs associated with these drugs.  
Methods: One hundred patients diagnosed with schizophrenia were recruited from outpatient 
psychiatry departments in Peshawar, Pakistan and followed for one year. Demographic data were 
collected for each patient at the beginning of the study. A questionnaire was used to collect 
antipsychotic prescription information at 4, 8 and 12 months. The cost of antipsychotics was obtained 
from PharmaGuide, Pakistan. The cost associated with antipsychotic drug use was statistically analyzed 
using post hoc tests. 
Results: Of the patients who completed this study, 68.1 % were prescribed second-generation 
antipsychotic (SGA) drugs, 6.9 % first-generation antipsychotic (FGA) drugs, and 25.0 % a combination 
of SGAs and FGAs. Furthermore, 40.3 % of the patients who completed the study received 
antipsychotic monotherapy and 34.7 % antipsychotic polytherapy. In monotherapy, risperidone was the 
most commonly prescribed antipsychotic drug, used by 44.8 % of patients while in polytherapy, 
risperidone plus olanzapine was the most commonly prescribed combination, used by 32 % of patients. 
Switching of antipsychotic drugs was observed in 25 % of patients. The mean annual cost of 
antipsychotic therapy was US$79.90 (8079 Pakistani rupees). Risperidone treatment cost was 
US$60.30 (PakRs 6095), constituting 52 % of the total monotherapy cost. The cost of SGAs was 
significantly higher than the cost of FGAs (p < 0.05). 
Conclusion: The results provide policymakers with appropriate information necessary for managing 
pharmacotherapy plans for the treatment of schizophrenia. 
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Schizophrenia is a severe mental disorder that 
affects the patient’s perceptions, language, 
behavior, and thinking [1]. A prolonged course of 
therapy is required to treat this disease, which 
can impose a significant financial burden on the 
patient and their family [2,3]. This is especially 
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true in low and middle income countries that lack 
treatment facilities such as nursing homes and 
community rehabilitation centers [4,5].  
 
Antipsychotic drugs account for much of the cost 
of schizophrenia treatment. The older, first-
generation antipsychotic (FGA) drugs are 
efficacious in treating the positive symptoms of 
schizophrenia and are relatively inexpensive. 
However, these drugs can cause serious side 
effects, such as extrapyramidal symptoms and 
tardive dyskinesia, which can lead to irreversible 
damage and non-compliance by the patient [1,6]. 
The newer, second-generation antipsychotic 
(SGA) drugs cause fewer side effects, are helpful 
in reducing the negative symptoms of 
schizophrenia, and are well tolerated by patients 
[7] but are costly compared to FGAs [8]. 
Schizophrenia may be treated with a single drug 
or a drug combination [9,10]. FGAs and SGAs 
are commonly co-prescribed [10], and this 
combination therapy has been shown to be 
effective in the treatment of acute psychotic 
symptoms.  
 
Antipsychotic drugs may be administered orally 
or via long-acting antipsychotic injection (LAI). 
LAIs have been shown to help prevent relapse 
and reduce hospitalizations [9,11] and are 
particularly useful in the 50–60% of 
schizophrenic patients who are noncompliant 
[12,13]. Combined oral administration of SGAs 
and LAI administration of FGAs has been shown 
to be particularly effective [13,14]. 
 
Variations in the prescribing pattern of 
antipsychotics exists among different countries 
due to factors including drug availability, efficacy, 
adverse effects, cost, and local prescription 
guidelines [15]. To date, no detailed study 
regarding antipsychotic use and its associated 
cost has been conducted in Pakistan. Therefore, 
this study will provide new insight into the 
antipsychotic prescribing practices in Pakistan 





This descriptive study was conducted in three 
major hospitals in the city of Peshawar, Khyber 
Pakhtun Khwa, Pakistan: the Sarhad Hospital for 
Psychiatric Diseases, Khyber Teaching Hospital, 
and Lady Reading Hospital. The study was 
approved by the ethical committee of Khyber 
Medical College, Peshawar (ref no. 
19/RD/Cell/KMC) and was conducted in 
accordance with the 1964 Helsinki declaration. 
Informed consent to participate in the study was 
obtained from all patients, and patient data were 
coded for confidentiality [16]. 
 
Using a convenience sampling method, 100 
patients were recruited into this study between 
July 2014 and June 2015. This sample size, 
calculated using the World Health Organization 
sample size calculator, takes into account the 
high dropout rate expected to occur over the 1-
year course of the study [17]. All patients 
included in the study were between 18 and 80 
years old, had a diagnosis of schizophrenia (ICD-
10 in the World Health Organization International 
Statistical Classification of Diseases and Related 
Health Problems classification system), and had 
at least one attendant. Patients with a co-morbid 
illness or with demographic data that were not 
credible were excluded from the study sample. 
As electronic patient medical records were not 
available in all of the selected hospitals, a 
questionnaire was developed to collect 
sociodemographic information and to record 
prescriptions of antipsychotics and other drugs. 
Patients and attendants were required to keep 
complete medical records during the 1-year 
course of the study and to complete the 
questionnaire at 4, 8 and 12 months, for a total of 
three assessments. Drug prices were obtained 




Patients were placed in three groups depending 
on the antipsychotic treatment regimen they 
received. Patients in Group I received 
antipsychotic monotherapy for the entire year. 
Patients in Group II received antipsychotic 
polytherapy. Patients in Group III switched from 
one treatment regimen to another during the 
course of the year.   
 
The type of antipsychotic drug or drug 
combination prescribed for each patient was 
assessed. Within each group, the number of 
patients receiving a particular type of 
antipsychotic treatment was measured, and the 
percentage of patients receiving that treatment 
was calculated based on the total number of 
patients in that group. The annual antipsychotic 
cost was calculated as the mean cost per day 
multiplied by the number of days the 
antipsychotic was used. Statistical Package for 
Social Sciences (SPSS version 20, Chicago IL-
USA) software was used calculates the mean 
annual antipsychotic prescription drug cost for all 
patients receiving a particular type of therapy 
using one-way ANOVA (post hoc analysis). For 
this study, a p-value of ≤ 0.05 was considered 
statistically significant. 
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Demographic and clinical variables 
 
Twenty-eight patients failed to return for follow-
up appointments and were excluded from the 
study, leaving 72 patients in the final study 
population. Demographic and clinical variables 
for patients in the final study population are 
shown in Table 1. In the final population, 67.7 % 
of patients were male. The majority of patients 
(63.9 %) were young adults between 18 and 38 
years of age. More than half of the patients (54.2 
%) were married, and most (62.5 %) were 
educated. At the time of enrollment in the study, 
the mean duration of illness was 2.8 years, and 
the mean positive and negative syndrome scale 
score was 77.6. 
 
Table 1: Demographic and clinical variables (N = 72) 
 
Variable N (%) 
Sex  
   Female 24 (33.3) 
   Male 48 (67.7) 
Age, years  
   18-38 46 (63.9) 
   39-59 24 (33.3) 
   60-80 2 (2.8) 
   Mean ± SD 33.6 ± 11 
Marital status  
   Unmarried 33 (45.8) 
   Married 39 (54.2) 
Education  
   Uneducated 27 (37.5) 
   Educated 45 (62.5) 
Duration of illness, 
years (mean ± SD) 
2.8 ± 1.3 






Antipsychotic Type  
   SGA 49 (68.1) 
   FGA 5 (6.9) 
   SGA + FGA 18 (25.0) 
  
A slight majority of patients (40.3 %) received 
monotherapy. The remaining patients (34.7 %) 
received polytherapy. SGAs alone were 
prescribed to 68.1 % of patients, FGAs alone 
were prescribed to 6.9 % of patients, and a 
combination of SGAs and FGA was prescribed to 
25 % of patients. 
 
Drug prescription patterns and associated 
costs 
 
The mean number of antipsychotics prescribed 
per patient was 1.4. Among the three study 
centers participating in this study, Khyber 
Teaching Hospital prescribed the lowest number 
of antipsychotics per patient (1.07). Lady 
Reading Hospital prescribed an average of 1.3 
antipsychotics per patient, and Sarhad Hospital 
for Psychiatric Diseases prescribed 1.8 
antipsychotics per patient. 
 
Table 2 shows the drug prescription pattern and 
average annual drug cost for patients receiving 
antipsychotic monotherapy (Group I). This group 
represents 40.3 % of the population. In this 
group, risperidone was the most commonly 
prescribed antipsychotic, used by 44.8 % of 
patients. The remaining patients were prescribed 
olanzapine (34.5 %), aripiprazole (10.3 %), 
haloperidol (6.9 %), and prochlorperazine (3.4 
%).  The mean cost of antipsychotic 
monotherapy was $ 52 USD (Rs. 5255). 
Risperidone treatment was the most expensive, 
costing $ 60.30 USD (Rs. 6095) and constituting 
52 % of the total monotherapy cost. Olanzapine 
treatment was the second most expensive, 
costing $ 59.70 USD (Rs. 6039). 
 
Table 2: Type of antipsychotic used and annual drug 
cost for patients in Group Ia 
 











   
Risperidone 13 
(44.8) 
60.3 ± 32 52.0 
Olanzapine 10 
(34.5) 
59.7 ± 34 39.6 
Aripiprazole 3 (10.3) 29.2 ± 7.1 5.8 
Haloperidol 2 (6.9) 15 ± 3.3 2.0 
       
Prochlorperazine 
1 (3.4) 8.4 0.6 
Sub-total 29 (100) 52.0 (33) 100 
aIncludes patients prescribed a single antipsychotic; 
bPercent of the 29 patients in Group I who were 
prescribed a particular drug; cCost in USD ($1 USD = 
101 Pak Rs.) 
 
Table 3 shows the drug prescription pattern and 
average annual drug cost for patients receiving 
antipsychotic polytherapy (Group II). This group 
represents 48.5 % of the final population. In this 
group, oral risperidone and oral olanzapine was 
the mostly prescribed drug combination (32 %), 
followed by oral risperidone and LAI fluphenazine 
(24 %). The mean cost of antipsychotic 
polytherapy was $103.20 USD (Rs. 10427). The 
most expensive polytherapy treatment, a 
combination of oral risperidone and oral 
olanzapine, cost $ 126.70 USD (Rs. 12797), or 
39 % of the mean polytherapy cost. 
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Table 3:  Types of antipsychotic used and annual drug cost for patients in Group IIa 
 
Antipsychotic Combination n (%)b Average annual 




Two antipsychotics     
Risperidone +d Olanzapine 8 (32) 126.7 ± 54.6 39.3 
 LAI Fluphenazine 6 (24) 84 ± 28 19.5 
 Quietipine 1 (4) 141.3  5.5 
 Aripiprazole 1 (4) 135 5.2 
     
Olanzapine +d LAI Fluphenazine 3 (12) 107 ± 46.6 12.5 
 Aripiprazole 4 16) 91.2 ± 12.3 14.1 
 Prochlorperazine 1 (4) 62.3 2.4 
     
Haloperidol +d LAI Fluphenazine 1 (40) 35.8 1.4 
Subtotal  25(100) 103.2 ± 43.9 100 
a Includes patients prescribed a combination of antipsychotics; bPercent of the 25 patients in Group II prescribed 
a particular drug; cCost in USD; + indicate a combination of antidepressant drugs. 
 
Table 4 shows the drug prescription pattern and 
average annual drug cost for patients who 
switched antipsychotic medications during the 
course of the study (Group III). Of the patients in 
this group, 22.2 % switched from a combination 
of oral risperidone and LAI fluphenazine to oral 
risperidone alone, and 22.2 % switched from a 
combination of oral olanzapine and LAI 
fluphenazine to a combination of oral olanzapine 
and oral haloperidol. Switching of other drug 
combinations occurred less frequently. The mean 
cost of antipsychotic therapy in patients who 
switched drugs was $ 92.70 USD (Rs. 9366). 
The highest cost was incurred by patients initially 
treated with an oral risperidone and LAI 
fluphenazine combination who then switched to 
oral risperidone monotreatment. Treatment for 
these patients cost an average of $ 77.50 USD 
(Rs. 7836), about 18.6 % of the antipsychotic 
cost for this group. 
 
Antipsychotic treatment patterns and cost 
analysis 
 
For the entire sample population, the mean 
annual cost of antipsychotics prescribed was 
US$79.90 (Pakistani rupees (Rs.) 8079). For 
SGAs used alone, the mean annual cost was 
US$ 80.29 (Rs. 8110). For FGAs used alone, the 
annual cost was $ 25.20 USD (Rs. 2554). For a 
combination of SGAs and FGAs, the mean 
annual cost was US$94.30 (Rs. 9528).  
 
Post hoc LSD analysis using one-way ANOVA 
was used to assess whether various treatment 
regimens differed significantly in cost. 
 
 
Table 4: Type of antipsychotic used and annual drug cost for patients in Group IIIa  
 
Antipsychotic  Switch to n (%)b Average costc 
(mean ± SD) 
Annual cost 
(%) 
Risperidone +dLAI Fluphenazine Risperidone 4 (22.2) 77.5 (13.8) 18.6 
Olanzapine + LAI Fluphenazine Olanzapine + Haloperidol 4 (22.2) 65 (18.7) 15.6 
Risperidone Risperidone + LAI 
Fluphenazine 
1 (5.6) 64.3 3.9 
Risperidone + Olanzapine + LAI 
Fluphenazine 
Risperidone + Olanzapine 1(5.6) 148.8 8.9 
Risperidone + Olanzapine  Olanzapine + LAI 
Fluphenazine 
1 (5.6) 241 14.4 
Olanzapine Olanzapine + LAI 
Fluphenazine 
1 (5.6) 106.6 6.4 
Olanzapine + Haloperidol Olanzapine 1 (5.6) 78 4.7 
Risperidone Olanzapine 1 (5.6) 172.2 10.3 
Aripiprazole  Risperidone 1 (5.6) 63 3.8 
Olanzapine Risperidone 2 (11.1) 86 (30.7) 10.3 
Olanzapine + Haloperidol Haloperidol 1 (5.6) 52 3.1 
Sub Total  18 (100) 92.7 (49.6) 100 
aIncludes patients switched from one antipsychotic treatment to another during the study period; bPercent of 
patients in Group III prescribed a particular drug out of a total of 18 patients; cCost in USD; d+ indicate a 
combination of antipsychotic drugs 
 
Khan et al 
Trop J Pharm Res, February 2018; 17(2): 343 
 
All treatment regimens used by only one patient 
were excluded from this analysis. There was no 
statistically significant difference in the mean cost 
of the various antipsychotics used for 
monotherapy [F(3, 24) = 1.9, p > 0.05] or in the 
cost of various antipsychotics used for 
polytherapy [F(3, 17) = 1.3, p > 0.05]. There was 
also no statistically significant difference in the 
mean cost of various antipsychotic drug 
treatments that were switched in the course of 
the study [F(2, 7) = 0.8, p > 0.05]. However, a 
significant difference in treatment cost was 
observed for patients in group I compared with 
group II (p < 0.05) and for patients in group I 
compared with group III (p < 0.05). No 
statistically significant difference in treatment 
cost was observed for patients in group II 





Antipsychotic monotherapy is recommended by 
most antipsychotic treatment guidelines [9,10]. In 
the present study, the percentage of patients 
receiving monotherapy was low compared with 
that in other countries [7,10,11]. The high 
incidence of polytherapy observed here may be 
due to the severity of symptoms; the patients 
from Sarhad Hospital for Psychiatrist Diseases 
who participated in this study were particularly 
unstable and may therefore have required more 
aggressive polytherapy treatment. Differences in 
study design may also account for the 
discrepancy in the number of patients receiving 
polytherapy. Tapp et al, for example, did not 
include drugs administered by LAI in the estimate 
of polytherapy treatment rates [10,18]. According 
to National Institute for Clinical Excellence, SGAs 
should be used as first-line antipsychotics in the 
treatment of schizophrenia. Clozapine, 
olanzapine, and risperidone are the most 
effacious and well tolerated SGAs in most 
schizophrenic patients. In our study, the majority 
of patients were prescribed SGAs. These results 
are consistent with the results from similar 
studies conducted in Australia, Bahrain, 
Germany, and the United States, where most 
schizophrenic patients were treated with SGAs 
[7,10,11,19,20]. 
 
Our study indicates that the use of antipsychotic 
polytherapy is similar between Pakistan and 
Finland.  Polytherapy is often used in the 
treatment of refractory schizophrenia. 
Polytherapy with FGAs and SGAs may be 
particularly effective because FGAs tend to act 
rapidly and may be able to quickly control 
psychotic symptoms until slower-acting SGAs 
become effective [10]. Polytherapy in which an 
SGA is administered orally and an FGA is 
administered by LAI is often recommended for 
patients who resist treatment [21]. However, the 
literature suggests that patient non-compliance is 
mainly due to the belief that side effects 
associated with LAI are worse than side effects 
associated with oral therapy [13].  
 
Polytherapy is also sometimes used early in 
treatment to manage the positive symptoms, and 
after these conditions are under control the 
patient is switched to SGA monotherapy. 
However a study conducted by Tapp et al [10] 
indicates that most psychiatrists found the FGA 
and SGA combination most effective and were 
therefore reluctant to switch from polytherapy to 
monotherapy. In this study, the rate of switching 
from one antipsychotic combination to another 
was 25 %. However, it is possible that some 
additional patients switched medications before 
the study began. The cost of SGAs in Pakistan is 
relatively low because most of the drugs are 
manufactured locally, although SGAs are still 
more expensive than FGAs [2,4,5]. Although 
SGA polytherapy, which typically combines an 
SGA and an FGA, can be considerably more 
expensive than monotherapy, the high cost of 
SGAs may be warranted, as it has been reported 
by Mauskopf and colleagues that treatment with 
SGAs reduces hospitalization and minimizes side 
effects, hence reducing overall medical cost and 
improving quality of life [22]. 
 
Limitations of the Study 
 
The study enrolled only a small number of 
patients. However, in a developing country, 





The present study assessed the economic cost 
of antipsychotics used in the treatment of 
schizophrenia in Pakistan. SGAs, which are the 
most frequently prescribed antipsychotic drugs, 
are costly compared to FGAs. The results of the 
present study can be used to assess the 
pharmacoeconomics of antipsychotic prescription 
practices and to afford policymakers with 
information necessary for developing successful 
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